|
1
|
Trescot AM: Review of the role of opioids
in cancer pain. J Natl Compr Canc Netw. 8:1087–1094.
2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Paice JA, Bohlke K, Barton D, Craig DS,
El-Jawahri A, Hershman DL, Kong LR, Kurita GP, LeBlanc TW,
Mercadante S, et al: Use of opioids for adults with pain from
cancer or cancer treatment: ASCO guideline. J Clin Oncol.
41:914–930. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fallon M, Giusti R, Aielli F, Hoskin P,
Rolke R, Sharma M and Ripamonti CI: ESMO Guidelines Committee.
Management of cancer pain in adult patients: ESMO clinical practice
guidelines. Ann Oncol. 29 (Suppl 4):iv166–iv191. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Novy DM, Nelson DV, Koyyalagunta D, Cata
JP, Gupta P and Gupta K: Pain, opioid therapy, and survival: A
needed discussion. Pain. 161:496–501. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Satija A, Ahmed SM, Gupta R, Ahmed A, Rana
SP, Singh SP, Mishra S and Bhatnagar S: Breast cancer pain
management-A review of current & novel therapies. Indian J Med
Res. 139:216–225. 2014.PubMed/NCBI
|
|
6
|
Koulouris AI, Banim P and Hart AR: Pain in
patients with pancreatic cancer: Prevalence, mechanisms, management
and future developments. Dig Dis Sci. 62:861–870. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Montazeri A: Quality of life data as
prognostic indicators of survival in cancer patients: an overview
of the literature from 1982 to 2008. Health Qual Life Outcomes.
7(102)2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mestdagh F, Steyaert A and Lavand'homme P:
Cancer pain management: A narrative review of current concepts,
strategies, and techniques. Curr Oncol. 30:6838–6858.
2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bradley A and Boland JW: Effects of
opioids on immune and endocrine function in patients with cancer
pain. Curr Treat Options Oncol. 24:867–879. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li Y, Sun L, Zhou Q, Lee AJ, Wang L, Zhang
R and Wang S: Effects of opioid drugs on immune function in cancer
patients. Biomed Pharmacother. 175(116665)2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Malafoglia V, Ilari S, Vitiello L, Tenti
M, Balzani E, Muscoli C, Raffaeli W and Bonci A: The interplay
between chronic pain, opioids, and the immune system.
Neuroscientist. 28:613–627. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Plein LM and Rittner HL: Opioids and the
immune system-friend or foe. Br J Pharmacol. 175:2717–2725.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang Y, Zhuang Y, DiBerto JF, Zhou XE,
Schmitz GP, Yuan Q, Jain MK, Liu W, Melcher K, Jiang Y, et al:
Structures of the entire human opioid receptor family. Cell.
186:413–427.e17. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Stein C: Opioid receptors. Annu Rev Med.
67:433–451. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Faouzi A, Varga BR and Majumdar S: Biased
opioid ligands. Molecules. 25(4257)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wassum KM, Ostlund SB, Maidment NT and
Balleine BW: Distinct opioid circuits determine the palatability
and the desirability of rewarding events. Proc Natl Acad Sci USA.
106:12512–12517. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pasternak GW and Pan YX: Mu Opioids and
their receptors: Evolution of a concept. Pharmacol Rev.
65:1257–1317. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Streicher JM and Bilsky EJ: Peripherally
acting µ-opioid receptor antagonists for the treatment of
opioid-related side effects: Mechanism of action and clinical
implications. J Pharm Pract. 31:658–669. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhou Q, Zhang Z, Long S, Li W, Wang B and
Liang N: Opioids in cancer: The κopioid receptor (Review). Mol Med
Rep. 25(44)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Peppin JF and Raffa RB: Delta opioid
agonists: A concise update on potential therapeutic applications. J
Clin Pharm Ther. 40:155–166. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Dai ZH, Xu X, Chen WQ, Nie LN, Liu Y, Sui
N and Liang J: The role of hippocampus in memory reactivation: An
implication for a therapeutic target against opioid use disorder.
Curr Addict Rep. 9:67–79. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yamamizu K, Hamada Y and Narita M: κ
Opioid receptor ligands regulate angiogenesis in development and in
tumours. Br J Pharmacol. 172:268–276. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jelic MD, Mandic AD, Maricic SM and
Srdjenovic BU: Oxidative stress and its role in cancer. J Cancer
Res Ther. 17:22–28. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rullo L, Caputi FF, Losapio LM, Morosini
C, Posa L, Canistro D, Vivarelli F, Romualdi P and Candeletti S:
Effects of different opioid drugs on oxidative status and
proteasome activity in SH-SY5Y cells. Molecules.
27(8321)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
de Almeida AS, Pereira GC, Brum EDS, Silva
CR, Antoniazzi CTD, Ardisson-Araújo D, Oliveira SM and Trevisan G:
Role of TRPA1 expressed in bone tissue and the antinociceptive
effect of the TRPA1 antagonist repeated administration in a breast
cancer pain model. Life Sci. 276(119469)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Skrabalova J, Drastichova Z and Novotny J:
Morphine as a potential oxidative stress-causing agent. Mini Rev
Org Chem. 10:367–372. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Schattauer SS, Bedini A, Summers F,
Reilly-Treat A, Andrews MM, Land BB and Chavkin C: Reactive oxygen
species (ROS) generation is stimulated by κ opioid receptor
activation through phosphorylated c-Jun N-terminal kinase and
inhibited by p38 mitogen-activated protein kinase (MAPK)
activation. J Biol Chem. 294:16884–16896. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Reuter S, Gupta SC, Chaturvedi MM and
Aggarwal BB: Oxidative stress, inflammation, and cancer: How are
they linked? Free Radic Biol Med. 49:1603–1616. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Waris G and Ahsan H: Reactive oxygen
species: Role in the development of cancer and various chronic
conditions. J Carcinog. 5(14)2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Boland JW and Pockley AG: Influence of
opioids on immune function in patients with cancer pain: From bench
to bedside. Br J Pharmacol. 175:2726–2736. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mizota T, Tsujikawa H, Shoda T and Fukuda
K: Dual modulation of the T-cell receptor-activated signal
transduction pathway by morphine in human T lymphocytes. J Anesth.
27:80–87. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gomez-Flores R and Weber RJ: Inhibition of
interleukin-2 production and downregulation of IL-2 and transferrin
receptors on rat splenic lymphocytes following PAG morphine
administration: A role in natural killer and T cell suppression. J
Interferon Cytokine Res. 19:625–630. 1999.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chen C, Farooqui M and Gupta K: Morphine
stimulates vascular endothelial growth factor-like signaling in
mouse retinal endothelial cells. Curr Neurovasc Res. 3:171–180.
2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Eisenstein TK: The role of opioid
receptors in immune system function. Front Immunol.
10(2904)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Tuerxun H and Cui J: The dual effect of
morphine on tumor development. Clin Transl Oncol. 21:695–701.
2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhang XY, Liang YX, Yan Y, Dai Z and Chu
HC: Morphine: Double-faced roles in the regulation of tumor
development. Clin Transl Oncol. 20:808–814. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhang H, Zhou D, Gu J, Qu M, Guo K, Chen W
and Miao C: Targeting the mu-Opioid receptor for cancer treatment.
Curr Oncol Rep. 23(111)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
McDonald J and Lambert DG: Opioid
receptors. BJA Education. 15:219–224. 2015.
|
|
39
|
Bimonte S, Barbieri A, Rea D, Palma G,
Luciano A, Cuomo A, Arra C and Izzo F: Morphine promotes tumor
angiogenesis and increases breast cancer progression. Biomed Res
Int. 2015(161508)2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Malik JA, Affan Khan M, Lamba T, Adeel
Zafar M, Nanda S, Owais M and Agrewala JN: Immunosuppressive
effects of morphine on macrophage polarization and function. Eur J
Pharmacol. 975(176637)2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tariq M, Zhang J, Liang G, Ding L, He Q
and Yang B: Macrophage polarization: Anti-cancer strategies to
target tumor-associated macrophage in breast cancer. J Cell
Biochem. 118:2484–2501. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Gach K, Szemraj J, Wyrębska A and Janecka
A: The influence of opioids on matrix metalloproteinase-2 and -9
secretion and mRNA levels in MCF-7 breast cancer cell line. Mol
Biol Rep. 38:1231–1236. 2011.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Malsy M, Hackl C, Graf B, Bitzinger D and
Bundscherer A: The effects of analgesics on the migration of
pancreatic cancer cells. In Vivo. 36:576–581. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
O'Sullivan S, Medina C, Ledwidge M,
Radomski MW and Gilmer JF: Nitric oxide-matrix metaloproteinase-9
interactions: Biological and pharmacological significance: NO and
MMP-9 interactions. Biochim Biophys Acta. 1843:603–617.
2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Nikitovic D, Corsini E, Kouretas D,
Tsatsakis A and Tzanakakis G: ROS-major mediators of extracellular
matrix remodeling during tumor progression. Food Chem Toxicol.
61:178–186. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Huang H: Matrix metalloproteinase-9
(MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent
advances. Sensors (Basel). 18(3249)2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Mehner C, Hockla A, Miller E, Ran S,
Radisky DC and Radisky ES: Tumor cell-produced matrix
metalloproteinase 9 (MMP-9) drives malignant progression and
metastasis of basal-like triple negative breast cancer. Oncotarget.
5:2736–2749. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ning J, Chen X, Li Q, Yang D, Xie C, Qin S
and Jiang H: Bidirectional effects of morphine on pancreatic cancer
progression via the p38/JNK pathway. Sci Rep.
14(24233)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Ma Y, Ren Z, Ma S, Yan W, He M, Wang D and
Ding P: Morphine enhances renal cell carcinoma aggressiveness
through promotes survivin level. Ren Fail. 39:258–264.
2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Jiang Y, Li T, Qian Y, Zuo X and Liu J:
Morphine in combination with ketamine improves cervical cancer pain
and suppresses immune function via the JAK3/STAT5 pathway. Pain Res
Manag. 2022(9364365)2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Liu X, Yang J, Yang C, Huang X, Han M,
Kang F and Li J: Morphine promotes the malignant biological
behavior of non-small cell lung cancer cells through the
MOR/Src/mTOR pathway. Cancer Cell Int. 21(622)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Koodie L, Ramakrishnan S and Roy S:
Morphine suppresses tumor angiogenesis through a HIF-1α/p38MAPK
pathway. Am J Pathol. 177:984–997. 2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Tripolt S, Neubauer HA, Knab VM, Elmer DP,
Aberger F, Moriggl R and Fux DA: Opioids drive breast cancer
metastasis through the δ-opioid receptor and oncogenic STAT3.
Neoplasia. 23:270–279. 2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Wei YC, Zhang B, Li X, Liu XM, Zhang J,
Lei B, Li B, Zhai R, Chen Q and Li Y: Upregulation and activation
of δopioid receptors promotes the progression of human breast
cancer. Oncol Rep. 36:2579–2586. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wang S: Historical review: Opiate
addiction and opioid receptors. Cell Transplant. 28:233–238.
2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Leconte C, Mongeau R and Noble F:
Traumatic stress-induced vulnerability to addiction: Critical role
of the dynorphin/kappa opioid receptor system. Front Pharmacol.
13(856672)2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Li H, Ma Z and Lei Y: The expression of
kappa-opioid receptor promotes the migration of breast cancer cells
in vitro. BMC Anesthesiol. 21(210)2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Eisenstein TK: Opioids and the immune
system: What is their mechanism of action? Br J Pharmacol.
164:1826–1828. 2011.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wang Q, Liu Z, Tang S and Wu Z: Morphine
suppresses the immune function of lung cancer by up-regulating MAEL
expression. BMC Pharmacol Toxicol. 23(92)2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Wang J, Barke RA, Charboneau R,
Schwendener R and Roy S: Morphine induces defects in early response
of alveolar macrophages to streptococcus pneumoniae by modulating
TLR9-NF-kappa B signaling1. J Immunol. 180:3594–3600.
2008.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Wang J, Ma J, Charboneau R, Barke R and
Roy S: morphine inhibits murine dendritic cell IL-23 production by
modulating toll-like receptor 2 and Nod2 signaling. J Biol Chem.
286:10225–10232. 2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Xie F, Kitagawa Y, Ogata H, Yasuhara S,
You Z and Jeevendra Martyn JA: Morphine induces inflammatory
responses via both TLR4 and cGAS-STING signaling pathways.
Cytokine. 183(156737)2024.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Malik JA and Agrewala JN: Morphine acts
via TLR4 resulting in neuroinflammation and immunosuppression. Med
Hypotheses. 186(111335)2024.
|
|
64
|
Singhal PC, Sharma P, Kapasi AA, Reddy K,
Franki N and Gibbons N: Morphine enhances macrophage apoptosis. J
Immunol. 160:1886–1893. 1998.PubMed/NCBI
|
|
65
|
Lin M, Deng K, Li Y and Wan J: Morphine
enhances LPSinduced macrophage apoptosis through a PPARγdependent
mechanism. Exp Ther Med. 22(714)2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Saurer TB, Carrigan KA, Ijames SG and
Lysle DT: Suppression of natural killer cell activity by morphine
is mediated by the nucleus accumbens shell. J Neuroimmunol.
173:3–11. 2006.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Saeed I, La Caze A, Hollmann MW, Shaw PN
and Parat MO: New Insights on Tramadol and Immunomodulation. Curr
Oncol Rep. 23(123)2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Maher DP, Walia D and Heller NM:
Suppression of human natural killer cells by different classes of
opioids. Anesth Analg. 128:1013–1021. 2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Khabbazi S, Goumon Y and Parat MO:
Morphine modulates interleukin-4- or breast cancer cell-induced
pro-metastatic activation of macrophages. Sci Rep.
5(11389)2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Yamamizu K, Furuta S, Hamada Y, Yamashita
A, Kuzumaki N and Narita M, Doi K, Katayama S, Nagase H, Yamashita
JK and Narita M: к Opioids inhibit tumor angiogenesis by
suppressing VEGF signaling. Sci Rep. 3(3213)2013.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Cho JS, Lee MH, Kim SI, Park S, Park HS,
Oh E, Lee JH and Koo BN: The effects of perioperative anesthesia
and analgesia on immune function in patients undergoing breast
cancer resection: A prospective randomized study. Int J Med Sci.
14:970–976. 2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Shi Y, Zhang Y, Yu S, Luo J, Pan Z, Wang X
and Tian J: Activation of kappa opioid receptor (KOR) inhibits
estrogen receptor (ER)-positive breast cancer through the
KOR-ER-XBP1 pathway. Biomed Pharmacother.
167(115462)2023.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Zhang HW, Wang F, Zhou YQ, Xu SP, Yu SY
and Zhang ZG: Morphine suppresses liver cancer cell tumor
properties in vitro and in vivo. Front Oncol.
11(666446)2021.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Wang L, Guo W, Guan H, Yan N, Cai X and
Zhu L: Tramadol suppresses growth of orthotopic liver tumors via
promoting M1 macrophage polarization in the tumor microenvironment.
Naunyn-Schmiedebergs Arch Pharmacol. 397:4205–4218. 2024.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Schwenk ES and Mariano ER: Designing the
ideal perioperative pain management plan starts with multimodal
analgesia. Korean J Anesthesiol. 71:345–352. 2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Morgan EL: Regulation of human B
lymphocyte activation by opioid peptide hormones. Inhibition of IgG
production by opioid receptor class (µ-, kappa-, and delta-)
selective agonists. J Neuroimmunol. 65:21–30. 1996.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Börner C, Warnick B, Smida M, Hartig R,
Lindquist JA, Schraven B, Höllt V and Kraus J: Mechanisms of
opioid-mediated inhibition of human T cell receptor signaling. J
Immunol. 183:882–889. 2009.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Beilin B, Shavit Y, Trabekin E, Mordashev
B, Mayburd E, Zeidel A and Bessler H: The effects of postoperative
pain management on immune response to surgery. Anesth Analg.
93:822–827. 2003.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Dahan A, van Lemmen M, Jansen S, Simons P
and van der Schrier R: Buprenorphine: A treatment and cause of
opioid-induced respiratory depression. Br J Anaesth. 128:402–404.
2022.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Kiyatkin EA: Respiratory depression and
brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin,
and fentanyl. Neuropharmacology. 151:219–226. 2019.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Abdel Shaheed C, Beardsley J, Day RO and
McLachlan AJ: Immunomodulatory effects of pharmaceutical opioids
and antipyretic analgesics: Mechanisms and relevance to infection.
Br J Clin Pharmacol. 88:3114–3131. 2022.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Saunders KW, Von Korff M, Campbell CI,
Banta-Green CJ, Sullivan MD, Merrill JO and Weisner C: Concurrent
use of alcohol and sedatives among persons prescribed chronic
opioid therapy: Prevalence and risk factors. J Pain. 13:266–275.
2012.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Leppert W: Pain management in patients
with cancer: Focus on opioid analgesics. Curr Pain Headache Rep.
15:271–279. 2011.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Boon M, van Dorp E, Broens S and Overdyk
F: Combining opioids and benzodiazepines: Effects on mortality and
severe adverse respiratory events. Ann Palliat Med. 9:542–557.
2020.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Chen A and Ashburn MA: Cardiac effects of
opioid therapy. Pain Med. 16 (Suppl 1):S27–S31. 2015.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu
J, She Q, Tan J, Lou C, Liao Z and Li X: mRNA vaccine in cancer
therapy: Current advance and future outlook. Clin Transl Med.
13(e1384)2023.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Szeto GL and Finley SD: Integrative
approaches to cancer immunotherapy. Trends Cancer. 5:400–410.
2019.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Wang Z and Cao YJ: Adoptive cell therapy
targeting neoantigens: A frontier for cancer research. Front
Immunol. 11(176)2020.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Topalian SL, Taube JM and Pardoll DM:
Neoadjuvant checkpoint blockade for cancer immunotherapy. Science.
367(eaax0182)2020.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Wang SJ, Dougan SK and Dougan M: Immune
mechanisms of toxicity from checkpoint inhibitors. Trends Cancer.
9:543–553. 2023.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Zhang H, Dai Z, Wu W, Wang Z, Zhang N,
Zhang L, Zeng WJ, Liu Z and Cheng Q: Regulatory mechanisms of
immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer
Res. 40(184)2021.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Waldman AD, Fritz JM and Lenardo MJ: A
guide to cancer immunotherapy: from T cell basic science to
clinical practice. Nat Rev Immunol. 20:651–668. 2020.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Shiravand Y, Khodadadi F, Kashani SMA,
Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K and
Kulasinghe A: Immune checkpoint inhibitors in cancer therapy. Curr
Oncol. 29:3044–3060. 2022.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Suresh K, Naidoo J, Lin CT and Danoff S:
Immune checkpoint immunotherapy for non-small cell lung cancer:
Benefits and pulmonary toxicities. Chest. 154:1416–1423.
2018.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Acharya C, Betrapally NS, Gillevet PM,
Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi
M and Bajaj JS: Chronic opioid use is associated with altered gut
microbiota and predicts readmissions in patients with cirrhosis.
Aliment Pharmacol Ther. 45:319–331. 2017.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Sacerdote P, Bianchi M, Gaspani L,
Manfredi B, Maucione A, Terno G, Ammatuna M and Panerai AE: The
effects of tramadol and morphine on immune responses and pain after
surgery in cancer patients. Anesth Analg. 90:1411–1414.
2000.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Swarm RA, Paice JA, Anghelescu DL, Are M,
Bruce JY, Buga S, Chwistek M, Cleeland C, Craig D, Gafford E, et
al: Adult cancer pain, version 3.2019, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 17:977–1077.
2019.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Mercadante S: Opioid analgesics adverse
effects: The other side of the coin. Curr Pharm Des. 25:3197–3202.
2019.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Weir A: Opioid-free anaesthesia. Br J Hosp
Med (Lond). 85:1–2. 2024.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Chen SH, Chen SS, Wang YP and Chen LK:
Effects of systemic and neuraxial morphine on the immune system.
Medicine (Baltimore). 98(e15375)2019.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Wang J, Barke RA and Roy S:
Transcriptional and epigenetic regulation of interleukin-2 gene in
activated T cells by morphine. J Biol Chem. 282:7164–7171.
2007.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Amodeo G, Bugada D, Franchi S, Moschetti
G, Grimaldi S, Panerai A, Allegri M and Sacerdote P: Immune
function after major surgical interventions: The effect of
postoperative pain treatment. J Pain Res. 11:1297–1305.
2018.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Wang Y, Wang X, Ye L, Li J, Song L,
Fulambarkar N and Ho W: Morphine suppresses IFN signaling pathway
and enhances AIDS virus infection. PLoS One.
7(e31167)2012.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Vassou D, Bakogeorgou E, Kampa M,
Dimitriou H, Hatzoglou A and Castanas E: Opioids modulate
constitutive B-lymphocyte secretion. Int Immunopharmacol.
8:634–644. 2008.PubMed/NCBI View Article : Google Scholar
|
